Medical Cost Analysis of Implantable Cardioverter Defibrillators for Primary Prevention Among Cardiac Arrest Patients
In this multicenter retrospective analysis, we identified a subset of patients who were eligible for primary prevention ICD therapy but did not receive it prior to experiencing sudden cardiac arrest. These cases were associated with substantial post-arrest medical costs. Our findings highlight the potential clinical and economic impact of the underutilization of ICDs in Japan and suggest that broader implementation of guideline-directed ICD therapy for primary prevention may reduce both mortality and healthcare expenditure.
Authors
- Toshinori Chiba (ORCID: https://orcid.org/0000-0002-2173-4519)
- James A. Coles
- Yoshio Kobayashi (ORCID: https://orcid.org/0000-0002-6268-6883)
- Makoto Osawa (ORCID: https://orcid.org/0000-0002-7661-2666)
- Yusuke Kondo (ORCID: https://orcid.org/0000-0002-1975-3796)
- Yohei Kawasaki (ORCID: https://orcid.org/0000-0002-7474-7647)
- Sayaka Ono (ORCID: https://orcid.org/0000-0002-3771-5005)
- Tadahiro Goto (ORCID: https://orcid.org/0000-0002-5880-2968)
- Masahiko Takagi (ORCID: https://orcid.org/0000-0001-7712-8529)
- Katsuhiko Imai (ORCID: https://orcid.org/0000-0002-8080-5698)
- Hiroshi Tada (ORCID: https://orcid.org/0000-0003-2670-8982)
- Satoaki Matoba
Institutions
- University of Fukui (JP)
- Kansai Medical University (JP)
- Chiba University (JP)
- University Medical Center (US)
- Medtronic (Ireland) (IE)
- Kyoto Prefectural University of Medicine (JP)
- Deutsches Herzzentrum der Charité (DE)
- Kure Medical Center (JP)
- Charité - Universitätsmedizin Berlin (DE)
- Saitama Medical University (JP)
Publication Details
- Journal
- Circulation Journal
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1253/circj.cj-25-0195
- Citations
- 1
- Primary Topic
- Cardiac pacing and defibrillation studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Boston Scientific Corporation
- Japan Lifeline
- Boston Scientific Japan
- Boehringer Ingelheim Japan
- Nipro
- Daiichi-Sankyo
- Astellas Pharma
- Otsuka Pharmaceutical
- Novartis Pharma
- Eli Lilly Japan
- Medtronic Japan
- Daiichi Sankyo Company
- Daiichi Sankyo Europe